| Name | Title | Contact Details |
|---|---|---|
Nicole Guido |
Executive Vice President, Client Experience | Profile |
Morehead Memorial Hospital operates as a community hospital that provides various medical services to patients in Eden, North Carolina. It offers birthing center, cancer center, cardiac rehabilitation and chronic disease management, cardiopulmonary, day hospital, diagnostic imaging, emergency, intensive coronary care unit, laboratory, nursing center, occupational health, rehabilitation, sleep center, diagnostic center, wound healing center, and women’s diagnostic services. The company was founded in 1960 and is headquartered in Eden, North Carolina.
Chicago Dentist- Providing Excellent Dental Care is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Nautilus Healthcare Management Group is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Hospital for Sick Children (SickKids) is recognized as one of the world’s foremost paediatric health-care institutions and is Canada’s leading centre dedicated to advancing children’s health through the integration of patient care, research and education. Founded in 1875 and affiliated with the University of Toronto, SickKids is one of Canada’s most research-intensive hospitals and has generated discoveries that have helped children globally. Our mission is to provide the best in complex and specialized family-centred care; pioneer scientific and clinical advancements; share expertise; foster an academic environment that nurtures health-care professionals; and champion an accessible, comprehensive and sustainable child health system. SickKids is proud of its vision of Healthier Children. A Better World.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.